MacroGenics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MacroGenics (Nasdaq: MGNX) announced its participation in two investor conferences in March 2022. The first event is the Cowen 42nd Annual Health Care Conference on March 8, where CEO Scott Koenig will join a panel discussion at 10:30 AM ET. The second is the Barclays Global Healthcare Conference on March 15, featuring a corporate overview at 3:50 PM ET. Both events will include one-on-one meetings and webcasts accessible via MacroGenics' investor relations website, with archived replays available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – MGNX
In the trading session that priced this news, MGNX declined 3.73%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2022:
- Cowen 42nd Annual Health Care Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Genitourinary Oncology Panel, Tuesday, March 8, 2022, at 10:30 am ET. Management will also participate in one-on-one meetings.
- Barclays Global Healthcare Conference. MacroGenics’ management is scheduled to participate in a fireside chat and provide a corporate overview on Tuesday, March 15, 2022, at 3:50 pm ET. Management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
